ABSTRACT
Background Type 2 diabetes and atherosclerotic cardiovascular disease share several risk factors. However, it is unclear whether the effect of these risk factors on liability to atherosclerotic cardiovascular disease is independent of their effect on liability to type 2 diabetes.
Methods We performed univariate Mendelian randomization to quantify the effects of continuous risk factors from the IEU OpenGWAS database on liability to three outcomes: type 2 diabetes, coronary artery disease, and peripheral artery disease, as well as the effects of liability to type 2 diabetes on the risk factors. We also performed two-step Mendelian randomization for mediation to estimate the mediating pathways between the risk factors, liability to type 2 diabetes, and liability to the atherosclerotic cardiovascular disease outcomes where possible.
Results We found evidence for 53 risk factors as causes of liability to coronary artery disease, including eight which were causes of liability to type 2 diabetes only and four which were consequences only. Except for fasting insulin and hip circumference, the direct and total effects from the two-step Mendelian randomization were similar. This suggests that the combination of these risk factors with liability to type 2 diabetes was unlikely to alter liability to coronary artery disease beyond their individual effects. We also found 13 risk factors that were causes of liability peripheral artery disease, including six which were causes of liability to type 2 diabetes only and four which were consequences only. Again, the direct and total effects were similar for these ten risk factors apart from fasting insulin.
Conclusions Most risk factors were likely to affect liability to atherosclerotic cardiovascular disease independently of their relationship with liability to type 2 diabetes. Control of modifiable risk factors therefore remains important for reducing atherosclerotic cardiovascular disease risk regardless of patient liability to type 2 diabetes.
What is already known about this subject?
Type 2 diabetes, coronary artery disease and peripheral artery disease, share several risk factors
Type 2 diabetes is also one of the strongest independent risk factors for both coronary and peripheral artery disease
What is the key question?
Which risk factors for atherosclerotic cardiovascular disease are mediated by liability to type 2 diabetes and which are independent?
What are the new findings?
Among 108 risk factors in this study, there was evidence to support: 10 risk factors as causes, 23 risk factors as consequences, and 34 risk factors as both causes and consequences of liability to type 2 diabetes
In addition, we found evidence for 53 risk factors as causes of liability to coronary artery disease and 42 risk factors as causes of liability to peripheral artery disease
Using two-step Mendelian randomization for mediation, we found most risk factors for atherosclerotic cardiovascular disease were likely to act independently of liability to type 2 diabetes
How might this impact on clinical practice in the foreseeable future?
Our findings support continued control of modifiable risk factors as this is likely to reduce atherosclerotic cardiovascular disease, regardless of patient liability to type 2 diabetes
Competing Interest Statement
TRG receives funding from Biogen for research unrelated to this manuscript. The authors of this manuscript have no other conflicts of interest to declare.
Funding Statement
VMW, ARC, NMD, GDS and TRG are members of the Medical Research Council Integrative Epidemiology Unit, which is supported by the Medical Research Council and the University of Bristol [MC_UU_00011/1, MC_UU_00011/4 and MC_UU_00011/6]. ARC is also supported by the University of Bristol British Heart Foundation Accelerator Award (AA/18/7/34219). NMD is also supported by a Norwegian Research Council [grant number 295989]. BFV is supported by the NIH/NIDDK (DK126194 and DK101478). M.S.U. is supported by NIDDK K23DK114551.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This manuscript used publicly available summary level data from previously published studies and so did not require specific IRB and/or ethics committee approval. Details of the IRB and/or ethics committee approval obtained for each contributing study can be found in their respective publications.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in this study are publicly available. We accessed genome-wide association study summary statistics for the risk factors from the IEU OpenGWAS database: https://gwas.mrcieu.ac.uk/; for liability to type 2 diabetes from the DIAMANTE consortium: https://www.diagram-consortium.org/; for liability to coronary artery disease from the CARDIoGRAM consortium: http://www.cardiogramplusc4d.org/; and for liability to peripheral artery disease from dbGAP: https://www.ncbi.nlm.nih.gov/gap/. Approved dbGAP access to phs001672.v6.p1 was provided to B.F.V. (dbGAP project ID: 27398). The code for this study has been made available on GitHub: https://github.com/venexia/T2DMediationMR.
